OMER — OMEROS CORP
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1285819 ·
Last close
$13.92
Market Cap
$1.01B
52W High
$21.24
52W Low
$6.70
ADV30
1,219,552
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 35,934,000 | 35,108,000 | 4,501,000 | -57,356,000 | 248,095,000 | 5,070,000 | 338,068,000 |
| Jun 2026 | 28,529,000 | 27,731,000 | 74,000 | 13,232,000 | 286,833,000 | 1,988,000 | 338,182,000 |
| Mar 2026 | 9,893,000 | 9,306,000 | -17,421,000 | 56,060,000 | 286,173,000 | 1,906,000 | 349,507,000 |
| Dec 2025 | 0 | — | -29,081,000 | 86,451,000 | 325,632,000 | 9,660,000 | 446,863,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-68,672,000
Investing CF
$136,819,000
Financing CF
$-68,063,000
CapEx
$-65,000
Dividends Paid
—
Buybacks
$-9,878,000
EPS Diluted TTM
$1.28
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-844,403,000
Inventory
$842,000
Receivables
$46,904,000
ST Investments
$129,965,000
EBIT TTM
$15,978,000
Pretax Income TTM
$118,631,000
Interest Exp TTM
$17,148,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$38,422,000
EBITDA
$-71,913,000
Free Cash Flow
$183,310,496
Enterprise Value
$1,488,175,360
Total Cash
$131,953,000
Total Debt
$296,870,016
Shares Out
72,388,316
Trailing EPS
$1.65
Book Value
$-0.71
ROE
—
ROA
-18.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -122,796,000 | -3,350,000 | 325,632,000 | 446,863,000 | -121,231,000 | -116,094,000 |
| Dec 2024 | 0 | -166,953,000 | -156,815,000 | 277,079,000 | 459,688,000 | -182,609,000 | -148,803,000 |
| Dec 2023 | 0 | -164,530,000 | -117,813,000 | 378,269,000 | 403,252,000 | -24,983,000 | 74,726,000 |
| Dec 2022 | 0 | -163,389,000 | 47,417,000 | 590,969,000 | 505,285,000 | 85,684,000 | -86,483,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$340,871,000
NetIncome TTM
$124,826,000
OpCashFlow TTM
—
Assets (Latest)
$286,833,000
Forward EPS
$1.15
Max Pain — expiry 2026-12-18
max pain strike: $12.00 · spot: $14.55 · call oi: 5,224 · put oi: 3,040
Expected Move to 2026-12-18:
±$2.52
(17.35%) —
implied range
$12.03 –
$17.08
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CYRX | Cryoport, Inc. | $999.81M | $19.74 | — |
| ANRO | Alto Neuroscience, Inc. | $999.16M | $24.91 | — |
| MTRI | InMed Pharmaceuticals Inc. | $1.02B | $17.50 | — |
| SVRA | Savara Inc | $988.39M | $4.48 | — |
| JBIO | Jade Biosciences, Inc. | $979.40M | $15.40 | — |
News headlines (Yahoo Finance, 1h cache)
Omeros (OMER) Just Gave Investors Another Reason to Sell
2026-11-18 06:11 · Yahoo
OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares
2026-11-17 17:12 · Yahoo
Omeros (OMER) Q3 2026 Earnings Call Transcript
2026-11-17 15:48 · Yahoo
Omeros Corporation Q3 2026 Earnings Call Summary
2026-11-17 13:30 · Yahoo
Omeros Corp (OMER) Q3 2026 Earnings Call Highlights: YARTEMLEA Sales Surge 30% as Operating ...
2026-11-17 05:01 · Yahoo
Omeros Q3 Earnings Call Highlights
2026-11-17 01:15 · Yahoo
Omeros falls 10% despite revenue beat
2026-11-16 21:50 · Yahoo
Omeros (OMER) Surpasses Q3 Earnings and Revenue Estimates
2026-11-16 21:15 · Yahoo
Omeros: Q3 Earnings Snapshot
2026-11-16 21:10 · Yahoo
Omeros Corporation Reports Third Quarter 2026 Financial Results
2026-11-16 21:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.